July 31, 2024

HEMGENIX Has Been Administered Across The U.S.

Administered in Green Bay

HEMGENIX is revolutionizing treatment with its groundbreaking one-time infusion that offers elevated and sustained factor IX levels for years. Approved by the FDA in 2022, HEMGENIX has been the focus of extensive research for many years, promising new hope for patients.

We are thrilled to highlight a significant achievement within our team. Andrea Buxton, APNP, one of HOC’s Nurse Practitioners, recently shared her invaluable insights on the preparation and administration experiences for the first two patients to be commercially dosed with HEMGENIX. Her contributions are not only a testament to her expertise but also underscore the innovative spirit that drives our organization.

For more information check out the FAQ’s from HEMGENIX website:

.

 

Recent Posts

The Evolution of Hemophilia Treatment with Dr. Ken Friedman

Today on Beyond the Bleeds, Heather and John are joined by Dr. Ken Friedman from Versiti Blood Center and HOC for a conversation about the evolution of hemophilia treatment. Drawing on decades of experience in hematology and bleeding disorders care, Dr. Friedman...

Out On The Town: Bleeding Disorders Awareness Edition

In this special episode of Beyond the Bleeds, Heather and John take bleeding disorder awareness beyond the clinic and into the community. From downtown Green Bay to St. Norbert College in De Pere, Wisconsin, they hit the streets to ask everyday people what they know...

Social Media